Galenica was co-founded in 1996 by its principal officers: James S. Manuso, Ph.D., MBA, President and Chief Executive Officer; Dante J. Marciani, Ph.D., D.Sc., Chairman and Chief Scientific Officer, one of the world's most renowned vaccinologists; and David Vigor, MBA, Chief Financial Officer. The Company's Scientific Advisory Board includes Dr. Phil Livingston of Memorial Sloan Kettering Cancer Center and Dr. Al LoBuglio, Director of the Comprehensive Cancer Center at the University of Alabama at Birmingham. Galenica Pharmaceuticals has developed its proprietary technology in immune enhancers, carriers and antigens, recognizing that multiple components are needed to develop effective vaccines. With these new therapeutic agents, physicians will be able to modulate the body's immune system to provide protection and treatment against an array of diseases. The company has assembled a strong technology base in medicinal chemistry and immunology to position itself as a major player in the expanding field of vaccines for cancer and infectious diseases. Galenica's laboratory facilities are located in Birmingham, Alabama.